S2-E42.1 – FGF Drugs in Development – A Promising Class of Agents

S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on FGF drug development to date.

After a simple opening from Roger Green, this conversation about FGF drugs in Development includes 4 key elements:

1:05 – Roger Green discusses recent history of FGF agents and podcast episodes discussing them
2:11 – Stephen Harrison discusses the efruxifermin BALANCED Phase 2a trial in F2/F3 NASH and Cohort C with cirrhosis patients
6:59 – Arun Sanyal and Stephen Harrison discuss future prospects for FGF-21 agents
10:34 – Arun Sanyal discusses specific receptor targets for different FGF agents and why they matter

This episode has specific discussions of efruxifermin and mentions of pegbelfermin and MK-3655, the former NGM-313.

The NASH Tsunami In Diabetes

Categories for NASH Tsunami
AASLD Allied Health Professionals Cirrhosis Clinical Trials Companies COVID-19 Diabetes Diagnostics Doctors Drugs/Drug Classes Drug therapies Endocrinology clinics Epidemiology Fatty Liver FDA FIB-4 GLP-1s Guidelines Hepatology Histopathology Inside The Vault Investors Liver Science Major Meetings Metabolic Diseases Motivating front-line treaters NAFLD NAFLD Prevalence NAIL-NIT NASH NASH-TAG NASH/Diabetes Co-Morbidity NITs Obesity Patient Advocacy Patients Pediatric NASH Podcast Prevalence/Incidence Public Health Rising Tide Science Special Subpopulations Suggested Reading Type 2 Diabetes Mellitus

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Stay In Touch
Apple Spotify Youtube